INTRODUCTION
According to published guidelines, hospitalized patients at risk of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia should receive empiric therapy for MRSA pending culture results. 1 The principal limitations of this approach are that 40% to 70% of patients fail to produce adequate respiratory tract samples, and the processing of sputum specimens takes 72 to 96 hours. 2, 3 Therefore, patients empirically initiated on an anti-MRSA antibiotic regimen will certainly receive it for several days and probably remain on it for a full course of therapy. Overuse of antibiotics is associated with increased costs, drug-drug interactions, toxicity, and the development of antibiotic resistance. 4, 5 Early identification of patients at very low risk of MRSA infection may spare them empiric antibiotic therapy directed against MRSA.
Nasal screening for MRSA with highly sensitive polymerase chain reaction (PCR) has a turnaround time of about one hour. 6 This test is largely used for epidemiologic purposes; its usefulness as a tool for clinical decision making remains unclear. Nasal PCR results may help guide initial empiric antibiotic therapy for respiratory tract infections because the nasopharynx is generally regarded as the source of pathogens in bacterial pneumonia.
This study addresses a remarkably simple and focused question, namely, whether the absence of nasal colonization with MRSA (using nasal MRSA PCR) can predict the absence of MRSA in lower respiratory tract secretions. We hypothesized that a negative nasal MRSA PCR correlates with the absence of MRSA in lower respiratory tract cultures, when both are collected within 48 hours of admission. If true, these results might guide empiric antimicrobial treatment of lower respiratory tract infection.
METHODS
We conducted a retrospective study of adult patients admitted to an urban teaching hospital ( 
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Nasal Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction: A Potential Use in Guiding Antibiotic Therapy for Pneumonia board approved the study. The institutional review board granted a waiver of individual informed consent.
Electronic medical records and laboratory data were reviewed. For each patient, we recorded age, sex, race, comorbid medical conditions, ICU admission, and inhospital mortality. The hospital microbiology laboratory (med fusion, Lewisville, TX) provided a list of patients with MRSA nasal PCR results and a second list of patients with lower respiratory tract cultures positive for S aureus (sputum, tracheal aspirate, bronchoalveolar lavage, or bronchial wash or brush). Nasal swab PCR for MRSA was processed using BD GeneOhm (Becton, Dickinson and Co, San Diego, CA) until May 2011, and then Roche LightCycler MRSA Advanced Test (Roche Diagnostics, Indianapolis, IN) until the end of the study. 6 Respiratory tract samples were cultured on blood, colistin nalidixic acid, chocolate, and MacConkey agar.
Sensitivity, specificity, and positive and negative predictive values were obtained for nasal MRSA PCR as the diagnostic test and lower respiratory tract culture as the gold standard for detecting MRSA in the lower respiratory tract. We calculated 95% confidence intervals on the basis of logit transformation.
RESULTS
Seventy-two patients met inclusion criteria. Demographic and clinical characteristics are shown in Table 1 . Lower respiratory tract samples included sputum (60%), tracheal aspirate (32%), and bronchoalveolar (8%) specimens. Forty-nine (68.1%) patients were admitted to the ICU, and 23 (31.9%) were admitted to the medical ward. Twentytwo (30.6%) patients died during the hospitalization.
Conditional probabilities are shown in Table 2 
DISCUSSION
A diagnostic test that correctly guides the discontinuation of empiric MRSAdirected antibiotic therapy must have a low false-negative rate, because a falsenegative nasal MRSA PCR test could result in discontinuing MRSA-directed antibiotic therapy in a patient who actually has MRSA lower respiratory tract infection. In other words, we are interested in a test with high sensitivity and negative predictive value. The results of this study show that MRSA nasal PCR screening within 48 hours of admission has high sensitivity, specificity, and positive and negative predictive value for the presence of MRSA in lower respiratory tract culture. Given the low incidence of S aureus community-acquired pneumonia (0.8%-3% in well-designed prospective studies), 3, 7 the nasal MRSA PCR test, with its high sensitivity and negative predictive value, could be a useful decision-making tool for clinicians to discontinue antibiotic coverage directed against MRSA early in admission. The principal benefits of the PCR screen include the ease of performing the nasal swab and rapid turnaround time. In addition, because respiratory tract samples are often difficult to obtain, the nasal MRSA PCR may be able to inform the discontinuation of MRSA-directed therapy in the absence of a respiratory tract sample.
Our study has several methodologic strengths. Unlike earlier investigators who obtained cultures from sputum and nonrespiratory sites (blood, incisions, and urine), 8 we focused exclusively on the clinically relevant association between S aureus colonization of the upper airways, in most cases the presumed source of bacteria that infect the lower respiratory tract, and the presence of MRSA in lower respiratory tract cultures. Secondly, we included only patients with lower respiratory tract cultures obtained within 48 hours of admission, thereby excluding patients with hospital-acquired infections. We also excluded patients transferred from another acute care facility for this reason.
Our study provides compelling data to undertake a more extensive prospective study. Moreover, the findings are consistent with a recent retrospective study in which the MRSA PCR test 
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Nasal Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction: A Potential Use in Guiding Antibiotic Therapy for Pneumonia had a sensitivity of 88% and a negative predictive value of 99.2% in predicting MRSA pneumonia. 9 In contrast to this study, however, our study restricted patients to those with a nasal PCR collected within 48 hours. We selected a cutoff of 48 hours because studies indicate that nasal colonization status changes soon after hospital admission. 10 The literature also suggests that nasal MRSA PCR has decreased sensitivity when clinical culture is obtained long after the PCR test. In a retrospective study of ICU patients by Byrnes et al, 8 the sensitivity of nasal PCR screening for MRSA in clinical cultures was only 69.5%. The sensitivity was most diminished by the inclusion of cultures obtained after 7 days from the initial nasal swab PCR test. In fact, nasal swab PCR screening for MRSA was most sensitive when clinical cultures were obtained within 6 days of the PCR (79% vs 46%, p < 0.0001). Furthermore, Sarikonda et al 11 determined that nasal screening with MRSA PCR was a poor predictor (sensitivity 24.2% and negative predictive value 84.4%) of ICU-acquired MRSA lower respiratory tract infections.
This study has certain limitations. We did not include all lower respiratory tract cultures, only those yielding S aureus. However, our negative predictive value (ie, the probability that a negative nasal MRSA PCR correctly predicts a negative lower respiratory tract culture for MRSA) can only increase if all positive results of lower respiratory tract cultures were included. Our study was retrospective at a single institution. Given the study's retrospective nature, we do not know the correlation between culture results and lower respiratory tract disease. Because our hospital does not mandate surveillance cultures, presumably physicians ordered lower respiratory tract cultures when they suspected a lower respiratory tract infection. Nevertheless, our findings are still useful because a negative nasal PCR early during admission means that cultures of the lower respiratory tract are exceedingly unlikely (< 5%) to yield MRSA. Even earlier collection of MRSA nasal PCR and respiratory tract culture may improve correlation between tests. In a prospective study, samples could be collected within hours of hospital arrival, and even in the absence of an adequate respiratory tract specimen, PCR might provide data quickly enough to inform antibiotic decision making at admission. Last, because of the small scale of this study, our data are hypothesis generating rather than definitive. Nonetheless, we believe that this study has important implications for antibiotic stewardship. It also provides preliminary data for the conduct of a definitive multicenter prospective clinical study.
CONCLUSION
Nasal PCR for MRSA collected within 48 hours of admission appears to reliably predict the absence of MRSA in lower respiratory tract secretions. This test may have a role in guiding the discontinuation of MRSA-directed empiric antibiotic therapy for patients hospitalized with lower respiratory tract infections. Even though the number of patients in our study is small, the high sensitivity and negative predictive value for MRSA nasal PCR in S aureus respiratory tract cultures is certainly suggestive that PCR for MRSA, when collected early in admission, reliably predicts the absence of MRSA in the lower respiratory tract. This warrants further exploration and a prospective study is needed to confirm these findings. v
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